Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

2006 Annual Meeting | Management of Common Behavioral Disturbances in Dementia

Sunday 04/02/06
06:00 PM - 09:00 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Dinner Seminar
Kimford J. Meador, MD, FÂ鶹´«Ã½Ó³»­
Cognitive Neurology/Neurologic Disorders Presenting with Psychiatric Symptoms
Upon Completion:
Participants should gain knowledge of the behavioral and pharmacological management of behavioral disturbances in patients with dementia.
No CME available
Medical Knowledge
Advanced
Practitioner, Fellow, Resident, Nurse
Event Timeline
06:00 PM - 06:10 PM Introduction
Kimford J. Meador, MD, FÂ鶹´«Ã½Ó³»­
06:00 PM - 09:00 PM Dinner
06:10 PM - 07:05 PM Behavioral Effects of Anti-dementia Agents
Jeffrey L. Cummings, MD, FÂ鶹´«Ã½Ó³»­
07:05 PM - 08:00 PM Role of Psychotropics in Treatment of Behavioral Disorders in Dementia
Daniel Kaufer, MD, FÂ鶹´«Ã½Ó³»­
08:00 PM - 08:40 PM Case Studies
Kimford J. Meador, MD, FÂ鶹´«Ã½Ó³»­
08:40 PM - 09:00 PM Questions and Case Studies From Audience
Faculty Disclosures
Kimford J. Meador, MD, FÂ鶹´«Ã½Ó³»­ The institution of Dr. Meador has received research support from NIH. The institution of Dr. Meador has received research support from The Epilepsy Consortium.
Jeffrey L. Cummings, MD, FÂ鶹´«Ã½Ó³»­ Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, ONO, Optoceutics, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, reMYND, Roche, Signant Health. Dr. Cummings has stock in Artery, Vaxxinity, Behrens, Alzheon, MedAvante-Prophase, and Acumen. Dr. Cummings has received research support from NIH. Dr. Cummings has received research support from NIGMS. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.
Daniel Kaufer, MD, FÂ鶹´«Ã½Ó³»­ No disclosure on file